AlloVir

$25.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+0.43%) Today
$0.00 (0.00%) As of 7:59 PM EDT after-hours

Why Robinhood?

You can buy or sell AlloVir and other stocks, options, and ETFs commission-free!

About ALVR

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. Read More The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX. The listed name for ALVR is AlloVir, Inc. Common Stock.

Employees
Headquarters
Houston, Texas
Founded
2013
Market Cap
1.58B
Price-Earnings Ratio
Dividend Yield
Average Volume
208.93K
High Today
$26.50
Low Today
$24.92
Open Price
$25.78
Volume
83.79K
52 Week High
$45.28
52 Week Low
$18.15

Collections

ALVR Earnings

-$4.43
-$2.95
-$1.48
$0.00
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 16, Pre-Market

You May Also Like